title: The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation.
abstract: Patients with advanced non-seminomatous germ cell tumors may achieve a serologic and radiographic complete response (CR) to first-line chemotherapy (defined as a residual mass < 1 cm in size). Recent reports suggest that these patients may be observed with a low rate of relapse but there remain compelling arguments for surgical excision. The arguments for and against post-chemotherapy retroperitoneal lymph node dissection (pcRPLND) are presented. There is clear consensus that patient's with residual masses > 1 cm should undergo post-chemotherapy surgery.
authors.affiliation: USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
authors.forename: Siamak
authors.initials: S
authors.lastname: Daneshmand
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Stephenson
authors.forename: Joel
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: Michael A S
authors.initials: MA
authors.lastname: Jewett
mesh_terms: D006801:Humans; D008197:Lymph Node Excision; D018365:Neoplasm, Residual / Q000601:surgery*; D009373:Neoplasms, Germ Cell and Embryonal / Q000601:surgery*; D012186:Retroperitoneal Neoplasms / Q000601:surgery; D012187:Retroperitoneal Space / Q000601:surgery; D013736:Testicular Neoplasms